Longevity Next

Trial

Bimagrumab obesity/T2D trial

Source-reviewed Last reviewed: 2026-10-02

Research Observatory

Evidence Update

Current evidence

Bimagrumab, compared with placebo in the NCT03005288 trial, reduced fat mass and increased lean mass over 48 weeks in adults with type 2 diabetes and obesity. Corrected metabolic findings do not establish improved strength or longevity.

What changed

Corrected placebo HbA1c is +0.04 percentage points; fat mass and body weight declined rather than increased.

What did not change

This is not the sarcopenia cohort, and 80% intervals must not be relabelled 95%.

Why it matters

Correction-aware trial intelligence prevents sign errors from surviving into profiles.

Main limitation

75 dosed participants, 58 completers, sex imbalance and adverse-event withdrawals.

Next proof

Larger clinical/function and safety confirmation.

Evidence reviewed through

Evidence release LNPG-REL-20261002-002

Sources

  1. Error in Discussion.

    Source type formal_correction Publication date 2021-02-12

    What this source establishes Corrects the bimagrumab trial's Discussion.

    Important limitation Amends the original study rather than adding independent evidence or removing its design limitations.

    Evidence access Correction notice reviewed.

  2. Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity: A Phase 2 Randomized Clinical Trial.

    Source type primary_research_publication Publication date 2021-01-13

    What this source establishes Reports fat-mass loss and lean-mass gain with bimagrumab versus placebo in adults with type 2 diabetes and obesity.

    Important limitation Small trial with attrition and sex imbalance; corrected values control, and lean mass is not strength.

    Evidence access Relevant full-text sections reviewed.

  3. Errors in Abstract, Table, and Discussion.

    Source type formal_correction Publication date 2021

    What this source establishes Corrects the bimagrumab trial's Abstract, table and Discussion, including metabolic values.

    Important limitation Corrected values govern interpretation; the reported intervals are 80%, not 95%, and this is not a new trial.

    Evidence access Correction notice reviewed.

Summary

NCT03005288 reported fat loss and lean-mass gain over 48 weeks in adults with T2D and obesity.

Intelligence Take

Correction-aware trial intelligence prevents sign errors from surviving into profiles.

Limitations

75 dosed participants, 58 completers, sex imbalance and adverse-event withdrawals.

Opens in a new tab